- Home
- SERA
as 03-28-2025 4:00pm EST
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SALT LAKE CITY |
| Market Cap: | 142.9M | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 97.9K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.99 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.52 - $12.36 | Next Earning Date: | 03-19-2025 |
| Revenue: | $77,000 | Revenue Growth: | -74.84% |
| Revenue Growth (this year): | 4536.36% | Revenue Growth (next year): | 411.43% |
Stock Insider Trading Activity of Sera Prognostics Inc. (SERA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Aerts Austin | SERA | Chief Financial Officer | Mar 7 '25 | Sell | $4.12 | 4,818 | $19,850.16 | 309,702 | |
| Harrison Robert Gardner | SERA | Chief Information Officer | Mar 7 '25 | Sell | $4.16 | 3,874 | $16,115.84 | 121,757 | |
| Lindgardt Zhenya | SERA | Chief Executive Officer | Mar 6 '25 | Sell | $4.12 | 29,722 | $122,454.64 | 876,657 | |
| Mirza Mansoor Raza | SERA | Director | Mar 6 '25 | Sell | $4.16 | 99 | $411.84 | 43,885 | |
| Boniface John J. | SERA | Chief Scientific Officer | Mar 5 '25 | Sell | $4.16 | 2,044 | $8,503.04 | 170,850 | |
| Kearney Paul | SERA | Chief Data Officer | Mar 5 '25 | Sell | $4.16 | 1,338 | $5,566.08 | 203,800 | |
| Jackson Benjamin | SERA | General Counsel | Mar 5 '25 | Sell | $4.16 | 2,285 | $9,505.60 | 138,544 | |
| Harrison Robert Gardner | SERA | Chief Information Officer | Mar 5 '25 | Sell | $4.16 | 3,251 | $13,524.16 | 121,757 | |
| Harrison Robert Gardner | SERA | Chief Information Officer | Feb 13 '25 | Sell | $4.28 | 3,610 | $15,450.80 | 121,757 | |
| Boniface John J. | SERA | Chief Scientific Officer | Feb 12 '25 | Sell | $4.58 | 5,915 | $27,090.70 | 170,850 |
Latest Sera Prognostics Inc. News
SERA Breaking Stock News: Dive into SERA Ticker-Specific Updates for Smart Investing
Simply Wall St.
8 days ago
Sera Prognostics Full Year 2024 Earnings: Misses Expectations
Zacks
10 days ago
Sera Prognostics, Inc. (SERA) Reports Q4 Loss, Misses Revenue Estimates
PR Newswire
10 days ago
SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN
PR Newswire
10 days ago
SERA PROGNOSTICS REPORTS FOURTH QUARTER 2024 FINANCIAL RESULTS
MT Newswires
16 days ago
Top Premarket Decliners
PR Newswire
18 days ago
Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2024 Financial Results on March 19, 2025
Simply Wall St.
a month ago
US Penny Stocks To Watch In February 2025
PR Newswire
a month ago
Sera Prognostics To Present at TD Cowen 45th Annual Health Care Conference
Compare SERA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SERA Sera Prognostics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.